RT Journal
A1 Holmes MV, Hingorani AD, Casas JP
T1 CYp2c19 genotype and cardiovascular events—reply
JF JAMA
JO JAMA
YR 2012
FD April 11
VO 307
IS 14
SP 1482
OP 1485
DO 10.1001/jama.2012.446
UL http://dx.doi.org/10.1001/jama.2012.446
AB 
In Reply:  We considered all included trials to be within the remit of our systematic review, including those involving patients receiving clopidogrel for indications other than PCI.1- 3 However, based on the letters from Dr Shuldiner and Dr Mega and their colleagues, we excluded these studies, which yielded a summary relative risk (RR) of 1.22 (95% CI, 1.11-1.33) for the association of CYP2C19 genotype with cardiovascular disease (CVD) events. The addition of the 3 studies alluded to by Mega et al, excluded by us because they focused solely on stent thrombosis, yielded a summary RR of 1.21 (95% CI, 1.12-1.30) for CVD events. These modest effect estimates also remain affected by small-study bias.